Chalid Assaf, MD, PhD, Helios Klinikum Krefeld, Krefeld, Germany, discusses the clinical outcomes of patients with advancedstage cutaneous (CTCL) lymphoma who are treated with lowdose gemcitabine. Dr Assaf describes how highdoses are associated with severe side effects, often resulting in discontinuation, leading to investigations into the efficacy of lowdose gemcitabine. Dr Assaf reports that lowdose gemcitabine has been shown to achieve a similar response rate to highdose gemcitabine, and is also able to achieve similar or even longer durations of response. Dr Assaf also comments on potential benefits of using lowdose gemcitabine in combination with mogamulizumab or brentuximab vedotin. This interview took place at the EORTC Cutaneous Lymphoma Group 2021 meeting in Marseille.